Intracavernous alprostadil alfadex - An effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study

International Journal of Impotence Research

Volumn 10, Issue 4, 1998, Pages 225-231

  Porst, H ^a   Buvat, J ^b   Meuleman, E ^c   Michal, V ^d   Wagner, G ^e  

^a Urological Office   (Germany)

^b Ctr d'Etud/Traitement de la Pathol de l'Appareil Reproducteur /de la Psychosomatique (CETPARP)   (France)

^c Academisch Zichenhuis   (Netherlands)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alprostadil Alfadex; Erectile dysfunction; Prostaglandin E1; Self injection therapy

Indexed keywords

PROSTAVASIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FIBROSIS; HEMATOMA; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PENIS DISEASE; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; SELF INJECTION; SEXUAL INTERCOURSE;

EID: 0032406017     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900365     Document Type: Article

References (38)

1. 1 for erectile dysfunction. J Urol 1996; 15: 80-81.
2. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction Int J Impot Res 1997; 9: 141-148.
3. Brindley GS. Cavernosal alpha-blockade: a new treatment for investigating and treating erectile impotence. Br J Psychiatry 1983; 143: 323-337.
4. 1 in the therapy of erectile dysfunction. VASA Suppl 1989; 28: 50-56.
5. Jünemann KP, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989; 1: 71-93.
6. Porst H. The rationale for prostaglandin E1 in erectile dysfunction. A survey of worldwide experience. J Urol 1996; 155: 802-815.
7. 1 in impotent men. J Urol 1988; 140: 66-68.
8. Molderings GJ, Van Ahlen H, Göthert M. Modulation of noradrenalin release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impot Res 1992; 4: 19.
9. Kifor J et al. Tissue angiotensin II as a modulator of erectile function. I angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920-1925.
10. Gerber GS, Levine LA. Pharmacological erection program using prostaglandin E1. J Urol 1991; 146: 786-789.
11. 1: a double-blind placebo-controlled, dose-response study. J Urol 1994; 151: 1530-1532.
12. 1 in erectile dysfunction. Clin Invest Med 1994; 72: 139-149.
13. Von Heyden B et al. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J Urol 1993; 149: 1288-1290.
14. Montague DK et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156: 2007-2011.
15. 1 and saline in primates. J Urol 1989; 142: 403-408.
16. 1 in patients with erectile dysfunction. J Urol 1997; 158: 1403-1407.
17. Van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharmakokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol 1994; 151: 1227-1230.
18. 1 for the treatment of erectile impotence. J Urol 1989; 141: 323-325.
19. 2 in man. J Biol Chem 1971; 246: 6713-6721.
20. Hedlund H, Andersson KE. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985; 134: 1245-1250.
21. Roy A et al. Prostaglandin 18-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Br J Urol 1989; 64: 180.
22. Girdley FM et al. Intracavernous self-injection for impotence. A long-term therapeutic option? Experience in 78 pts. J Urol 1988; 140: 972-974.
23. Lakin MM et al. Intracavernous injection therapy: Analysis of results and complications J Urol 1990; 143: 1138-1141.
24. 1). J Urol 1992; 147: 309A: 385.
25. Levine SB et al. Side-effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54-57.
26. Tullii RE, Degni M, Pinto AFC. Fibrosis of the cavernous bodies following intracavernous auto-injection of vasoactive drugs. Int J Impot Res 1989; 1: 49-54.
27. Ernst E, Pittler MH. Yohimbine for erectile dysfunctions systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 156: 433-436.
28. R). Int J Impot Res 1996; 8: D85.
29. R (Alprostadil) in the treatment of erectile dysfunction (ED): an 18 months study. Abstract book 2nd Meeting European. Society for Impotence Research October 1-4, 1997; 20: 37.
30. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994; 43: 844-848.
31. Padma-Nathan H et al. Treatment of men with erectile dysfunction with transurethral alprostadil Medicated Urethral System for Erection (MUSEstudy Group) N Engl J Med 1997; 336: 1-7.
32. R (medicated urethral system for erection) vs. intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187-192.
33. Werthman P, Rajfer J. MUSE Therapy: Preliminary clinical observations. Urology 1997; 50: 809-811.
34. R study group. Long-term safety profile of transurethral alprostadil for the treatment of erectile dysfunction. J Urol 1997; 157, Suppl 203: 792.
35. R. October 1-4, 1997; Madrid.
36. R) a new oral agent for the treatment of male erectile dysfunction. J Urol 1997; 157: 701.
37. Heaton JPW et al. Apomorphine SL is effective in the treatment of non-organic erectile dysfunction: results of a multicenter trial. Int J Impot Res 1997; 8: 115 A 64.
38. R) in erectile dysfunction results of a German multicenter-study in 177 patients. Int J Impot Res 1997; 3: 117A72.